

See IDS

VIA EFS

002298-0003-101 (CHROMO/003)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Kambiz Shekdar et al.
Application No. : 10/589,052
Confirmation No. : 5470
Filed or 371(c) Date : September 8, 2008
For : METHODS AND MATERIALS USING SIGNALING PROBES
Group Art Unit : 1654
Examiner : Amber D. Steele

East Palo Alto, California
September 2, 2011

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants make of record the following documents:¹

U.S. Patent Document

2003/096322

05-22-2003

Giuliano et al.

¹

A complete Form PTO/SB/08A listing these documents is attached hereto.

Foreign Patent Document

WO 200131059 05-03-2001 Molecular Light Tech Res Ltd.

Non-Patent Documents

BRAASCH et al., "Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design", Nucleic Acids Research, 30(23): 5160-5167 (2002)

GAIT, "Peptide-mediated cellular delivery of antisense oligonucleotides and their analogues", CMLS, Cell. Mol. Life Sci. 60:844-853 (2003)

GOPALAKRISHNAN et al., "siRNA and DNA Transfer to Cultured Cells", Methods in Molecular Biology, 480: 31-52 (2009)

HOFFMANN et al., "Expression screening of factors binding to the osteocalcin bone-specific promoter element OC Box I: isolation of a novel osteoblast differentiation-specific factor," J. Cell. Biochem. 80:156-168 (2000)

KURRECK, "Antisense technologies: Improvement through novel chemical modifications", Eur. J. Biochem. 270:1628-1644 (2003)

MITCHELL, "Turning the spotlight on cellular imaging", Nature Biotechnology, 19(11): 1013-1017 (2001)

NESTEROVA et al., "Killing the Messenger: Antisense DNA and siRNA", Current Drug Targets, 5: 683-689 (2004)

PESTOV et al., "Genetic selection of growth-inhibitory sequences in mammalian cells," Proc. Natl. Acad. Sci. USA 91:12549-12553 (1994)

ROSE, "Optimization of Transfection", Current Protocols in Neuroscience (1997) A.1B.1-A.1B.3

STARK et al., "Forward genetics in mammalian cells: function approaches to gene discovery," Human Molecular Genetics 8(10):1925-1938 (1999)

ZAMBROWICZ et al., "Disruption and sequence identification of 2,000 genes in mouse embryonic stem cells," Nature 392:608-611 (1998)

ZHENG et al., "A system for rapid generation of coat color-tagged knockouts and defined chromosomal rearrangements in mice," Nucl. Acids Res. 27(11):2354-2360 (1999)

Pursuant to 37 C.F.R. § 1.98(a)(2)(ii), applicants have provided copies of the documents listed above that are not U.S. patents or U.S. patent application publications.

Applicants respectfully request that these documents be: (1) fully considered by the Examiner during the examination of this application; and (2) printed on any patent that may issue from this application. Applicants request that a copy of the enclosed Form PTO/SB/08a, as considered and marked by the Examiner, be forwarded to the undersigned with the next communication.

Applicants hereby authorize the Director to charge the \$180.00 fee set forth in 37 C.F.R. § 1.17(p). 37 C.F.R. § 1.97(c)(2). The Director is authorized to charge payment of any fee required, or credit any overpayment, in connection with this Statement, to Deposit Account No. 06-1075, Order No. 002298-0003-101.

Respectfully submitted,

/WYAN-CHING M. LEE/

Jane T. Gunnison (Reg. No. 38,479)
Attorney for Applicants
Wyan-Ching M. Lee (Reg. No. 65,813)
Agent for Applicants
ROPES & GRAY LLP
Customer No. 81098